Tesffi.esuks ,, ; * % AR226-2129 file:///C|AVINDOWS/TEMP/RD C -81-3-79 thiu 4-30-811 pageitm 10f 2 T est R esu lts Sample Dale Range Concentration Range Action Level Industrial Hygiene 1/3/79 100% 4/30/81 Sample Dt Semple # Duration Type Employee Name Per* BTO : LOC : 17 RESEARCH 019 WEIGH AND ADD 0 8 TO POLYKETTLE 1/3779 47531 Z 1/4/79 47S32 Z Chemical Cone Unit Percent 0 8 <0.05 PPM 0.0% 0 8 <0.05 PPM 0.0% BTO : LOC : 17 RESEARCH 065 PPD SEM IW O RKS 4/6/81 57356 Z 0 8 <0.0001 PPM 0.0% BTO: LOC : 17 RESEARCH 100 P/S - EPM W AREHOUSE - FORK TRUCK OPERATION 4/30/81 60221 Z 0 8 0.0001 PPM 0.0% BTO: LOC : 17 RESEARCH 103 P/S FP POLLYKETTLE OPERATOR (17LG) 1/19/79 48192 Z 1/26/79 48193 Z 11/11/80 31069 P none 11/12/80 31070 P none 11/15/80 31071 P none 11/17/80 31072 P none 11/18/80 31073 P none 0 8 0.05 PPM 0.0% C-8 <0.01 PPM 0.0% C-8 <0.0001 PPM 0.0% 0 8 0.0005 PPM 0.0% 0 8 0.0005 PPM 0.0% 0 8 <0.0001 PPM 0.0% 0 8 <0.0001 PPM 8/28/2001 5:07PM E ID 129294 AJP0G6927 */ Test&?

AR226-2227 ,/?

AR226-2481 Roger J Zipfel 11/08/2000 02:35 PM To: sham rockl @wirefire.com cc: Subject: Results from extraction studies Jeff, I just got the results of m y extraction stud ies.

AR226-3175 DuPont-6010 TRADESECRET Study TUUs H-24516: Static, Acute, 48-Hour Screening Test to Daphnia magna LaboratoryProject ID: DuPont-6010 A u th o r : Robert A.

TRADE SECRET DuPont-8861 AR226-3212 Study Title H-25134: Static, Acute, 96-Hour Screening Test to Oncorhynchus mykiss Laboratory Project ID: DuPont-8861 Author: Laurie D.

yfK 2 2 6 ^ ZQGR p.i 3M Companv 1IPI-0027 Page I of 20 Date: January 9, 2006 Final Report Epidemiology, 220-6W-08 Medical Department 3M Company St.

P-1 R aaG - 362Z IN TERIM REPORT # 23 - Analysis o f Sedim ent Samples STUDY TITLE Analysis o f Perfluorobutanesulfonate (PFBS), Periluorohexanesulfonate (PFHS), and Perfluorooctanesulfonate (PFOS) in Water, Soil, Sediment, Fish, Clams, Vegetation, Small Mammal Liver and Small Mammal Serum Using LC/MS/MS for the 3M Decatur Monitoring Program .

Katherine E.

3M ENVIRONMENTAL LABORATORY REPORT NO.

GRAIN SIZE DISTRIBUTION 100 95 90 85 80 75 70 . 65 60 m>- 55 O' 50 z 45 HI UCLJ 40 35 30 25 20 15 10 5 U S.

3 February 2009 Draft Selection Criteria to identify Key In Vivo Mammalian Studies that Inform Dose-Response Modeling for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)a Study Feature Chemical, purity, matrix/medium Peer review Study design, execution, and reporting Study subject: species, strain, and sensitivity for given endpoint; litter; life stage; gender Exposure route Dose level Exposure frequency, duration, and timing Controls Response Statistical evaluation Selection Rationale Primary*3 Secondary^ TCDD-only doses included, purity specified, TCDD purity or matrix not clearly identified matrix in which TCDD is administered is identified Independently peer-reviewed, publicly available Supplementary materials accompanying peer-reviewed publication Clearly documented and consistent with standard Testing protocol provides incomplete toxicological principles, testing protocols, coverage of relevant endpoint-specific and practice (i.e., endpoint-appropriate, measures, particularly for negative findings particularly for negative findings) Mammalian species Mammalian species, in vivo, but only Strain and gender identified studying an artificially sensitive subject Animal age at beginning of treatment identified (e.g., knockout mouse) Litter confounders (within/between) accounted for Currently Excluded Studies of dioxin-like compounds (DLCs) or mixtures Not formally peer-reviewed; literature not publicly available Studies not meeting standard principles and practices Non-mammalian or not in vivo Oral Parenteral (e.g., intravenous, intramuscular, Inhalation, dermal, ocular intraperitoneal, subcutaneous) Lowest dose <200 ng/kg-d for noncancer endpoints and <1 ^g)/kg-d for cancer Lowest dose >200 ng/kg-d for noncancer endpoints, or >1.0 ^.g/kg-d for cancer Dosing regimen characterized and explained Characterization/explanation missing or cannot be determined Appropriate and well characterized Effect reported, but with no negative control Effect relevant to human health Magnitude outside range of normal variability Precursor effects, or adaptive responses Lethality potentially relevant to human health Clearly described and appropriate to the endpoint Limited statistical context and study design (e.g., per error variance, magnitude of effect) a NAS (2006) commented that the selection of data sets for quantitative dose-response modeling needed to be more transparent.

Cable Viewer Viewing cable 05BRASILIA3026, SLOW GOING ON BIOTECH, BUT MONSANTO LOOKING AT If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others.

FORM S-910 Sales Summary -- Ponds By Month (thousands) DIRECT #2 #1 SALESMEN S SALES BY CUSTOMER A.

To: From: Cc: Bcc: Received Date: Subject: wagner@api.org <wagner@api.org> Fitzsimmons, Mark <MFitzsimmons@steptoe.com> Clegg, Patsy M SCC-DCS/22 <patsy.clegg@shell.com> 2007-05-1023:35:02 GMT FW: Shanghai Health Study - Conference call on Thursday, May 17 at 1 PM EDT My potential conflict has turned into a real one.

To: whiter@api.org <whiter@api.org> From: ottowong@aol.com <ottowong@aol.com> Cc: Cagen, Stuart Z SHLOIL-SHOIL-SHS <stuart.cagen@shell.com>; Jmricewas@aol.com <Jmricewas@aol.com>; jarnotb@api.org <jarnotb@api.org>; Clegg, Patsy M SCC- DCS/22 <patsy.clegg@shell.com> Bcc: Received Date: 2007-05-27 16:38: 59 GMT Subject: Re: Emailing: Cinpathogen 2007-102814 Appendix B Milestones 5-21-07 Dear Russ, Jerry and Stuart: I was not aware of the new arrangement with University of Colorado.